Docality.com Logo
 
Dr. Maureen  Brown  Msn,Aprn,Bc,Fnp image

Dr. Maureen Brown Msn,Aprn,Bc,Fnp

1605 E Broadway Suite 260
Columbia MO 65201
572 422-2221
Medical School: Other - Unknown
Accepts Medicare: No
Participates In eRX: No
Participates In PQRS: No
Participates In EHR: No
License #: RN070547
NPI: 1437115441
Taxonomy Codes:
208800000X

Request Appointment Information

Awards & Recognitions

About Us

Practice Philosophy

Conditions

Medical Malpractice Cases

None Found

Medical Board Sanctions

None Found

Referrals

None Found

Publications

The role of cumulative growth hormone exposure in determining mortality and morbidity in acromegaly: a single centre study. - Pituitary
Acromegaly has traditionally been associated with significant mortality and cardiovascular morbidity. The aim of this study was to assess the overall mortality and improvement in mortality and morbidity in acromegaly and correlate these with cumulative growth hormone exposure.All patients treated for acromegaly at our centre until 2012 were analysed in this retrospective observational study. Baseline demographic details such as age at diagnoses, radiological features and pituitary status were obtained on these 167 patients. Cumulative GH levels (GHy) were calculated as a sum of average of GH readings in consecutive years. Mortality rates and development of new diabetes, hypertension and cardiovascular events (stroke, congestive cardiac failure and ischaemic heart disease) were assessed.The SMR for overall cohort was 1.6. There has been a significant improvement in SMR over the past two decades (SMR until 1992 2.5; SMR since 1992 1.0). Cumulative GH exposure was significantly high in patients who died (35.2 vs 24.1, p < 0.01) and in those with incident metabolic or vascular events during follow up (51.6 vs 24.4, p = 0.0001). The cardiovascular event rate of the 'new' cohort was significantly better than the 'old' cohort (8.0 vs. 29.1 %, p < 0.001).There has been significant improvement in mortality and morbidity associated with acromegaly, in the setting of routine care in a specialized endocrine unit. Early and effective treatment to 'control' acromegaly could reduce GH exposure and hence vascular comorbidities.
Using support workers to release time for qualified midwives in maternity care. - Nursing times
Maternity services must meet the demands of an increasingly diverse and rapidly growing population. Recent policy changes mean midwives are taking on roles formerly performed by doctors, leaving maternity support workers to undertake many traditional midwifery tasks. This article discusses how MSWs can facilitate choice by helping midwives deliver a flexible, personalised service to childbearing women and how the MSW role has developed.
A nurse-led clinic in chronic and allergic contact dermatitis. - British journal of nursing (Mark Allen Publishing)
It has generally been acknowledged that the incidence and prevalence of contact dermatitis has increased in recent years. It can develop at any stage of a person's life span (rare before puberty), and in many different circumstances and occupations. The demand on consultant dermatologists for contact dermatitis services has resulted in the depletion of some essential components to the investigation process, and patient outcomes have been affected. In recent years it has also resulted in the development of nurse-led contact dermatitis services. The traditional role of the dermatology nurse in contact dermatitis is to carry out patch testing. Nurse-led services require the wider acquisition of skills and knowledge in relation to contact dermatitis. This article is an attempt to introduce the complexities of contact dermatitis, and nurse-led services.
In vitro and in vivo gene transfer with poly(amino acid) vesicles. - Journal of controlled release : official journal of the Controlled Release Society
Non-viral gene delivery systems utilise either amine lipids or polyamines and although non-viral gene delivery systems are said to have a superior safety profile to viruses, the polyamines such as poly(L-lysine) are toxic when used without derivatisation and usually require specific receptor mediated uptake and/or endosomolytic agents to be effective. However, the conversion of poly(L-lysine) and poly(L-ornithine) polyamino acids into amphiphilic vesicle forming polymers reduces the toxicity of the polyamino acids and enables the resulting polyamino acid vesicles to deliver genes both in vitro and in vivo in the absence of receptor specific ligands and endosomolytic agents. The incorporation of a distearoylphosphatidylethanolamine poly(ethylene glycol)-galactosamine conjugate (with the galactosamine unit at the distal end of the poly(ethylene glycol) moiety) into the polyamino acid formulations improved in vitro gene transfer in the case of the amphiphilic poly(L-ornithine) (POP) although no in vivo targeting was detected with the galactosamine formulations. We conclude that the conversion of poly(L-lysine) and poly(L-ornithine) into amphiphilic colloid forming molecules reduces their toxicity, thus allowing these systems to be used for gene transfer in vivo. It is possible that this approach may be extended to other polyamines.

Map & Directions

1605 E Broadway Suite 260 Columbia, MO 65201
View Directions In Google Maps

Nearby Doctors

200 Portland St
Columbia, MO 65201
573 864-4600
1 Hospital Dr Dc095
Columbia, MO 65201
573 842-2123
1 Hospital Dr
Columbia, MO 65201
573 822-2568
1 Hospital Dr
Columbia, MO 65201
573 828-8885
1 Hospital Dr
Columbia, MO 65201
573 821-1201
1705 E Broadway Suite 100
Columbia, MO 65201
573 747-7800
1700 E Pointe Dr Ste 300
Columbia, MO 65201
573 431-1525
1 Hospital Dr Dc018.00, Ma101
Columbia, MO 65201
573 828-8885
800 Hospital Dr
Columbia, MO 65201
573 146-6000
402 N Keene St Ste 101
Columbia, MO 65201
573 826-6921